TWI347325B - Novel phosphonic acid based prodrugs of pmea and its analogues - Google Patents

Novel phosphonic acid based prodrugs of pmea and its analogues

Info

Publication number
TWI347325B
TWI347325B TW092132408A TW92132408A TWI347325B TW I347325 B TWI347325 B TW I347325B TW 092132408 A TW092132408 A TW 092132408A TW 92132408 A TW92132408 A TW 92132408A TW I347325 B TWI347325 B TW I347325B
Authority
TW
Taiwan
Prior art keywords
pmea
analogues
phosphonic acid
acid based
based prodrugs
Prior art date
Application number
TW092132408A
Other languages
English (en)
Chinese (zh)
Other versions
TW200426152A (en
Inventor
K Raja Reddy
Mark D Erion
Michael C Matelich
Joseph J Kopcho
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of TW200426152A publication Critical patent/TW200426152A/zh
Application granted granted Critical
Publication of TWI347325B publication Critical patent/TWI347325B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65742Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW092132408A 2002-05-13 2003-11-18 Novel phosphonic acid based prodrugs of pmea and its analogues TWI347325B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38054502P 2002-05-13 2002-05-13
PCT/US2003/014821 WO2004037161A2 (en) 2002-05-13 2003-05-12 Cyclic prodrugs of pmea one of its analogues

Publications (2)

Publication Number Publication Date
TW200426152A TW200426152A (en) 2004-12-01
TWI347325B true TWI347325B (en) 2011-08-21

Family

ID=32176361

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092132408A TWI347325B (en) 2002-05-13 2003-11-18 Novel phosphonic acid based prodrugs of pmea and its analogues

Country Status (9)

Country Link
US (1) US7214668B2 (enExample)
EP (2) EP1532157A4 (enExample)
JP (1) JP4476811B2 (enExample)
AU (1) AU2003299492B2 (enExample)
CA (1) CA2485702C (enExample)
IL (2) IL164809A0 (enExample)
NZ (1) NZ536328A (enExample)
TW (1) TWI347325B (enExample)
WO (1) WO2004037161A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2485597C (en) 2002-05-13 2013-07-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
EP1556393B1 (en) * 2002-10-31 2013-12-25 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
WO2005072748A1 (en) * 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1753762B1 (en) * 2004-06-08 2014-03-19 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
WO2006055525A2 (en) * 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
EP1907391A1 (en) 2005-07-26 2008-04-09 Hetero Drugs Limited Novel process for acyclic phosphonate nucleotide analogs
US20070042501A1 (en) * 2005-08-20 2007-02-22 Institute Of Nuclear Energy Research A novel technology for the purity assay of TRODAT-1 raw material
EA016995B1 (ru) * 2006-05-16 2012-09-28 Джилид Сайэнс, Инк. Соль карбоновой кислоты фосфонамидного производного 2,6-диаминопурина, способы и средства для лечения новообразований и лечения злокачественных новообразований крови, набор, стерильный водный раствор и композиция
CN101371841A (zh) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 结晶型恩替卡韦制剂及其制备方法和应用
JP2009196959A (ja) * 2008-02-25 2009-09-03 Yamaguchi Univ がん治療用医薬組成物
CN101475594B (zh) * 2009-02-06 2012-05-30 廖国超 肝靶向抗病毒前体药物环状磷酸酯及其应用
CN101659676B (zh) * 2009-09-07 2012-06-20 徐奎 一种硫代阿德福韦、替诺福韦肝靶向酯前体药物
US8940313B2 (en) 2010-04-23 2015-01-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
CN103221037A (zh) * 2010-11-12 2013-07-24 葛兰素惠尔康制造业私人有限公司 新药物组合物
BR112013014485B1 (pt) 2010-12-10 2021-03-30 Sigmapharm Laboratories, Llc Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
WO2012154698A2 (en) 2011-05-06 2012-11-15 Mckenna Charles E Method to improve antiviral activity of nucleotide analogue drugs
WO2013095684A1 (en) 2011-12-22 2013-06-27 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN103333209B (zh) * 2013-07-05 2015-09-30 西安新通药物研究有限公司 替诺福韦前药(hts)新晶体
CN104710477A (zh) * 2013-12-16 2015-06-17 安徽贝克联合制药有限公司 替诺福韦环膦酸酯化合物及其药学上可接受的盐和其制备方法及应用
CA2937548C (en) 2014-02-13 2022-10-25 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CN107540710B (zh) * 2016-06-24 2020-10-16 浙江柏拉阿图医药科技有限公司 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
WO2017220028A1 (zh) * 2016-06-24 2017-12-28 浙江柏拉阿图医药科技有限公司 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
CN108863797B (zh) * 2018-07-02 2021-01-15 吉首大学 一类3-(取代/非取代苯基)-3-羟基丙酰氧肟酸的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE554888A (enExample) 1956-12-20
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
FR2562543B1 (fr) 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
EP0353692B1 (en) 1988-08-02 1995-10-04 Nissan Chemical Industries Ltd. Drug effect-enhancing agent for antitumor drug
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5514798A (en) 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
DE69435319D1 (de) 1993-09-17 2010-12-16 Gilead Sciences Inc Nukleotidanaloge
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
DE4445829A1 (de) 1994-12-22 1996-06-27 Leybold Ag Gegenstrom-Schnüffellecksucher
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
DK0871454T3 (da) 1995-07-17 2004-03-22 Cephalon Inc Phosphorholdige inhibitorer af cystein- og serinprotease
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
IL133461A (en) 1997-07-25 2005-05-17 Gilead Sciences Inc Adefovir dipivoxil compositions
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
KR100818845B1 (ko) 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
NZ512219A (en) 1998-12-24 2004-12-24 Metabasis Therapeutics Inc A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
DK1165570T3 (da) 1999-03-05 2006-12-18 Metabasis Therapeutics Inc Nye phosphorholdige prodrugs
EP1210354A1 (en) * 1999-09-08 2002-06-05 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
NZ536942A (en) 2000-07-21 2006-03-31 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
CA2485597C (en) * 2002-05-13 2013-07-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
EP1556393B1 (en) 2002-10-31 2013-12-25 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
RS51476B (sr) * 2003-12-30 2011-04-30 Gilead Sciences, Inc. Fosfonati, monofosfonamidati, bisfosfonamidati za lečenje virusnih oboljenja
EP1753762B1 (en) * 2004-06-08 2014-03-19 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters

Also Published As

Publication number Publication date
US7214668B2 (en) 2007-05-08
AU2003299492A1 (en) 2004-05-13
CA2485702A1 (en) 2004-05-06
JP2006511490A (ja) 2006-04-06
NZ536328A (en) 2007-11-30
WO2004037161A3 (en) 2005-03-31
AU2003299492B2 (en) 2010-06-10
EP2223927A2 (en) 2010-09-01
IL164809A0 (en) 2005-12-18
US20030229225A1 (en) 2003-12-11
EP2223927B1 (en) 2014-10-15
EP1532157A2 (en) 2005-05-25
WO2004037161A2 (en) 2004-05-06
EP1532157A4 (en) 2009-02-25
EP2223927A3 (en) 2010-09-15
JP4476811B2 (ja) 2010-06-09
TW200426152A (en) 2004-12-01
CA2485702C (en) 2011-07-19
IL164809A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
TWI347325B (en) Novel phosphonic acid based prodrugs of pmea and its analogues
HRP20040853A2 (en) Phosphate prodrugs of fluorooxindoles
ZA200210271B (en) Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
IL164371A0 (en) Bisphosphonic acid for the treatment and prevention of osteoporosis
EP1569895A4 (en) PROGRUGS OF GABA ANALOGUE, COMPOSITIONS AND ITS USES
IL173382A0 (en) Amino acid prodrugs
PL371526A1 (en) Phosphorus-containing compounds and uses thereof
IL165100A0 (en) Prodrugs of excitatory amino acids
IL164810A (en) Process for preparation of cyclic prodrugs of pmea and pmpa
AU2002364932A8 (en) Calcium phosphate particles as mucosal adjuvants
EP1487776A4 (en) ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
GB2413556B (en) A new crystal form of adefovir dipivoxil and its composition
IL161476A (en) Phosphonic acid compounds as inhibitors of serine proteases
HK1074049A (en) Novel phosphonic acid based prodrugs of pmea and its analogues
PL366978A1 (en) Hydroxyfattysulfonic acid analogs
AU2003280271A8 (en) Phosphinic acid analogs of glutamate
AU2003289782A1 (en) Valproic acid analogues and pharmaceutical compositions thereof
AU2003266264A8 (en) Diphenyl ether and n-(phosphonomethyl)glycine herbicidal compositions and methods of use
AU2003240137A8 (en) Novel phosphonocarboxylic acid esters
PL361197A1 (en) New analogues of panthotenic acid and method for manufacture of new analogues of panthotenic acid
AU2003267733A1 (en) Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid
ZA200309678B (en) Prodrugs of gaba analogs compositions and uses thereof
IL152163A0 (en) Watersoluble prodrugs of propofol
HK1067074A (en) Phosphate prodrugs of fluorooxindoles
PL373284A1 (en) Analogues of vitamin d

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees